Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
基本信息
- 批准号:10556322
- 负责人:
- 金额:$ 67.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-25 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAnimalsBacille Calmette-Guerin vaccinationBiological ProductsCD4 Positive T LymphocytesCellsChimeric ProteinsChronicContainmentDataDenileukin DiftitoxDiphtheria ToxinDiseaseFOXP3 geneGranulomaHIVHIV InfectionsHIV/TBHumanIL2 geneIL2RA geneIL4 geneIL4R geneITGAM geneImmunosuppressive AgentsImmunotherapyIndolesLungMaintenanceMethodsModelingMusMycobacterium tuberculosisMyeloid-derived suppressor cellsNecrosisOryctolagus cuniculusPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacotherapyPlayProcessProliferatingResearchRoleSpleenSuppressor-Effector T-LymphocytesSystemTechnologyTuberculosisVaccine AdjuvantVirus Replicationcancer therapyefficacy evaluationglobal healthimprovednovelnovel therapeuticspathogenpreventreactivation from latencysingle-cell RNA sequencingtranslational applicationstuberculosis drugstuberculosis granulomatuberculosis immunity
项目摘要
PROJECT SUMMARY
Tregs and MDSCs have emerged as key suppressor cells that inhibit effector immunity in the TB granuloma.
In addition, Tregs have been implicated in the maintenance of HIV latency. We have generated two selective
biologic agents for potent depletion of Tregs and and MDSCs using diphtheria toxin (DT) fusion protein
technology: DT-IL2 targets IL2-R-positive (CD25+) cells (Tregs), and DT-IL4 targets IL4-R positive (CD124+)
cells (MDSCs). Our preliminary data demonstrate that: (i) DT-IL2 and DT-IL4 reduce the abundance of Treg and
MDSC cells, respectively, in mouse lungs and spleens, (ii) DT-IL2 and DT-IL4 reduces the ability of M. tb to
proliferate in an acute murine TB infection model, (iii) the drug, tasquinimod which has potent anti-MDSC activity,
reduced the ability of M. tb to proliferate in an acute TB infection model with a concomitant reduction in MDSCs,
and (iv) administration of DT-IL2 to CD4+ T cells from patients with controlled HIV reactivates viral replication.
These data support the hypotheses that (1) Tregs and MDSCs play important inhibitory roles in M. tb
containment, and (2) that Treg cells play a role in HIV latency maintenance. A central scientific premise of this
application is that further definition of the immunosuppressive roles of Tregs and MDSCs in TB and HIV infection
will reveal important immunopathogenesis mechanisms that may be exploited towards developing improved
host-directed therapies (HDTs) for both diseases. In this proposal we seek to address this premise by pursuing
the following aims. Aim 1: define the role of Treg cells in the TB granuloma using targeted CD25+ cell depletion
with DT-IL2. We will (a) evaluate the cellular composition of both cellular (C57BL/6, WT which are sst1R) and
necrotic (C57BL/6 sst1S) murine granulomas with and without CD25+ cell depletion using single-cell RNA-Seq
(SSRS) as well as traditional methods, (b) evaluate the efficacy of targeted CD25+ cell depletion in chronic
murine TB with and without anti-TB drug therapy, and (c) evaluate the contribution of Treg cells to the process
of cavitation (granuloma breakdown) using a novel model of rabbit cavitary TB. Aim 2: define the role of
MDSCs in the TB granuloma using targeted CD124+ cell depletion with DT-IL4. We will (a) evaluate the cellular
composition of both cellular and necrotic murine granulomas with and without CD124+ cell depletion using SSRS
as well as traditional methods, (b) evaluate the efficacy of targeted CD124+ cell depletion in chronic murine TB
with and without anti-TB drug therapy, (c) assess the impact of dual CD25+ and CD124+ cell depletion in the TB
granuloma with B6 sst1R and sst1S mice using SSRS as well as traditional methods, and (d) evaluate the
efficacy of dual CD25+ and CD124+ cell depletion in chronic murine TB with and without anti-TB drug therapy.
Aim 3: conduct translational applications of CD25+ cell depletion with (i) BCG vaccination and (ii) HIV
reactivation. We will (a) evaluate the efficacy of targeted CD25+ cell depletion as a vaccine adjuvant prior to
BCG vaccination and (b) evaluate the impact of targeted CD25+ cell depletion on HIV reactivation in PBMCs
from patients with controlled HIV infection.
项目摘要
结核分枝杆菌和MDSC已经成为抑制结核肉芽肿中效应免疫的关键抑制细胞。
此外,TdR与HIV潜伏期的维持有关。我们选择了两个
使用白喉毒素(DT)融合蛋白有效消耗THP和MDSC的生物制剂
技术:DT-IL 2靶向IL 2-R阳性(CD 25+)细胞(THBE),DT-IL 4靶向IL 4-R阳性(CD 124+)
细胞(MDSC)。我们的初步数据表明:(i)DT-IL 2和DT-IL 4降低Treg的丰度,
DT-IL 2和DT-IL 4分别降低小鼠肺和脾中M. tb到
在急性鼠TB感染模型中增殖,(iii)具有有效抗MDSC活性的药物他喹莫德,
降低了M. tb在急性TB感染模型中增殖并伴随MDSC的减少,
和(iv)将DT-IL 2给予来自控制HIV的患者的CD 4 + T细胞再激活病毒复制。
这些数据支持了以下假设:(1)TGFAP和MDSC在M. TB
遏制,和(2)Treg细胞在HIV潜伏期维持中发挥作用。一个核心的科学前提是
应用是进一步确定TcB和MDSC在TB和HIV感染中的免疫抑制作用
将揭示重要的免疫发病机制,可用于开发改善的
针对这两种疾病的宿主导向疗法(HDTs)。在本提案中,我们寻求通过以下方式解决这一前提:
以下目标。目的1:使用靶向CD 25+细胞去除来确定Treg细胞在TB肉芽肿中的作用
DT-IL2我们将(a)评估细胞(C57 BL/6,WT,其为sst 1 R)和
使用单细胞RNA-Seq检测CD 25+细胞耗竭和未耗竭的坏死性(C57 BL/6 sst 1 S)鼠肉芽肿
(B)评估靶向CD 25+细胞耗竭在慢性炎症中的功效,
用和不用抗TB药物治疗的鼠TB,和(c)评估Treg细胞对该过程的贡献
的空洞(肉芽肿破裂),使用一种新的模型,兔空洞结核病。目标2:确定
使用DT-IL 4靶向CD 124+细胞耗竭的TB肉芽肿中的MDSC。我们将(a)评估细胞
使用SSRS进行CD 124+细胞去除和未去除的细胞和坏死性鼠肉芽肿的组成
与传统方法一样,(B)评估靶向CD 124+细胞耗竭在慢性鼠TB中的功效
(c)评估双重CD 25+和CD 124+细胞耗竭在TB患者中的影响,
使用SSRS以及传统方法,用B6 sst 1 R和sst 1 S小鼠的肉芽肿,和(d)评估
双重CD 25+和CD 124+细胞去除在有和没有抗TB药物治疗的慢性鼠TB中的功效。
目的3:利用(i)BCG疫苗接种和(ii)HIV进行CD 25+细胞耗竭的翻译应用
重新激活我们将(a)评估靶向CD 25+细胞耗竭作为疫苗佐剂的有效性,
BCG疫苗接种和(B)评估靶向CD 25+细胞耗竭对PBMC中HIV再活化的影响
艾滋病病毒感染得到控制的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM Ramses BISHAI其他文献
WILLIAM Ramses BISHAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM Ramses BISHAI', 18)}}的其他基金
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
- 批准号:
10557906 - 财政年份:2022
- 资助金额:
$ 67.28万 - 项目类别:
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
- 批准号:
10484064 - 财政年份:2022
- 资助金额:
$ 67.28万 - 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
- 批准号:
10431023 - 财政年份:2022
- 资助金额:
$ 67.28万 - 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
- 批准号:
10593152 - 财政年份:2022
- 资助金额:
$ 67.28万 - 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:作为具有抗菌活性的宿主导向疗法的双重作用
- 批准号:
10686328 - 财政年份:2020
- 资助金额:
$ 67.28万 - 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
- 批准号:
10012368 - 财政年份:2020
- 资助金额:
$ 67.28万 - 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:具有抗菌活性的宿主导向疗法的双重作用
- 批准号:
10456845 - 财政年份:2020
- 资助金额:
$ 67.28万 - 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
- 批准号:
10320031 - 财政年份:2020
- 资助金额:
$ 67.28万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 67.28万 - 项目类别:
Research Grant